India, April 16 -- Switzerland's Basilea Pharmaceutica Ltd, (BPMUF,0QNA.L), which is focused on severe bacterial and fungal infections, announced Wednesday favorable results from treatment with fosmanogepix in patients with serious or life-threatening invasive fungal infections.
The company further said it looks forward to the start of its second phase 3 study with fosmanogepix covering a broad range of mold infections, including aspergillosis, fusariosis and mucormycosis.
Basilea presented new data for fosmanogepix, as well as isavuconazole (Cresemba) and ceftobiprole (Zevtera), at European Society of Clinical Microbiology and Infectious Diseases or ESCMID Global 2025 in Vienna, Austria.
Regarding fosmanogepix, a clinical-stage broad-sp...